Tag: ASX:BLS

BLS Pharmaceuticals Delivers Record FY26 as Global Growth Strategy Gains Momentum

by Psychedelics.Media Team

July 27, 2026

Newly rebranded BLS Pharmaceuticals (ASX:BLS) has capped off a transformational financial year, reporting record revenue, profitability and operating cash flow ...

No Result

View All Result

Home
News
Business
Policy & Regulation
Research
Health & Therapy
Opinion
Contact

Not enough quota to unlock this post

Unlock left : 0

Tag: ASX:BLS

BLS Pharmaceuticals Delivers Record FY26 as Global Growth Strategy Gains Momentum

Newsletter

Stay Ahead of Psychedelic Medicine

Recommended

Definium Therapeutics to Present Results From Three Phase 3 LSD Trials at Psychiatry Congress

Europe Faces the Next Big Test in Psychedelic Medicine: Can Public Healthcare Deliver Equitable Access?

Popular Story

Incannex and the Next Test for Psychedelic Medicine

BLS Pharmaceuticals expands commercial leadership with new Strategic Partnership Director

The Global Psychedelic Medicine Conference & Events Calendar 2026–2027

Eli Lilly Reportedly Nears Acquisition of AtaiBeckley in Potential Landmark Deal for Psychedelic Medicine

AbbVie’s $906M Psychedelic Bet: What It Means for Psychedelic Medicine

Recent Posts

Categories

Free Weekly Newsletter

Not enough quota to unlock this post

Are you sure want to cancel subscription?